Novo Nordisk AS (HAM:NOVA) Common Stock: €60 Mil (As of Mar. 2026)


HAM:NOVA Novo Nordisk AS HAM:NOVA
83 GF Score
Price €43.94
GF Value €121.46
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Common Stock?

Novo Nordisk AS HAM:NOVA +2.90% 83 Common Stock is €60 Mil as of Mar. 2026. GuruFocus rates HAM:NOVA with a GF Score™ of 83/100 and a GF Value™ of €121.46 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Novo Nordisk AS's quarterly common stock declined from Sep. 2025 (€60 Mil) to Dec. 2025 (€60 Mil) and declined from Dec. 2025 (€60 Mil) to Mar. 2026 (€60 Mil).

Novo Nordisk AS's annual common stock declined from Dec. 2023 (€61 Mil) to Dec. 2024 (€60 Mil) and declined from Dec. 2024 (€60 Mil) to Dec. 2025 (€60 Mil).

Novo Nordisk AS Common Stock Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Common Stock Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.13 61.29 60.51 59.80 59.72

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.80 59.78 59.76 59.72 59.67
HAM:NOVA
83GF Score
Novo Nordisk AS HAM:NOVA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €60 Mil mean?
Novo Nordisk AS (HAM:NOVA) has a Common Stock of €60 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Common Stock too high?
Novo Nordisk AS's current Common Stock is €60 Mil. Overall, Novo Nordisk AS has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Common Stock compare to LLY and JNJ?
Novo Nordisk AS's Common Stock of €60 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Common Stock is €60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €121.46, compared to a current price of €43.94 — trading 63.8% below its estimated fair value. The current Common Stock is €60 Mil. Novo Nordisk AS's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current Common Stock is €60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.94 is trading 63.8% below its estimated GF Value™ of €121.46. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOVA:

  • Common Stock: €60 Mil
  • GF Value™: €121.46 vs. price of €43.94 (63.8% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
83GF Score

Get the complete analysis for HAM:NOVA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.94
Price
€121.46
GF Value